DPP-IV is an enzyme responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)
Patients deemed inappropriate for treatment receive explanations of clinical concerns and may receive recommendations for alternative weight management approaches including referral to specialists, suggestion of comprehensive lifestyle modification programs, or guidance toward addressing underlying medical conditions before reconsidering pharmacological intervention
Nausea that had resolved during week four might reappear in the first week of month two
Allergic Reactions : Though rare, some people may have allergic reactions to the medication, such as rash, itching, or swelling
Before that, multiple companies have encountered obstacles in their efforts to develop treatments for hyperphagia in Prader-Willi syndrome
The brand states it does not contain GLP-1 or synthetic GLP-1 and is not a GLP-1 agonist drug